Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
Stifel Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $16
Stifel analyst Dae Gon Ha maintains $Inozyme Pharma(INZY.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 46.0% and a total
This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Inozyme Pharma Initiated at Buy by Stifel
Stifel Initiates Inozyme Pharma(INZY.US) With Buy Rating, Announces Target Price $16
Stifel analyst Dae Gon Ha initiates coverage on $Inozyme Pharma(INZY.US)$ with a buy rating, and sets the target price at $16.According to TipRanks data, the analyst has a success rate of 46.0% and
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins FuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Inozyme Draws Buy at Jefferies on Rare Disease Opportunity
Jefferies Initiates Inozyme Pharma(INZY.US) With Buy Rating, Announces Target Price $17
Jefferies analyst Maury Raycroft initiates coverage on $Inozyme Pharma(INZY.US)$ with a buy rating, and sets the target price at $17.According to TipRanks data, the analyst has a success rate of 40.2%
Inozyme Pharma: A Buy Rating With Multi-Billion Dollar Market Potential and Upcoming Catalysts
Express News | Inozyme Pharma Inc : Jefferies Assumes Coverage With Buy Rating; Target Price $17 Vs $16
Institutional Owners May Consider Drastic Measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) Recent US$49m Drop Adds to Long-term Losses
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)
Inozyme Pharma: A Strong Buy on Promising Treatments for Rare Disorders
TD Cowen Maintains Inozyme Pharma(INZY.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Inozyme Pharma(INZY.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.8% and a total average return of 17.7% over the
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Inozyme Pharma: A Buy Rating Backed by Clinical Trials and Market Potential
Needham Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $23
Needham analyst Joseph Stringer maintains $Inozyme Pharma(INZY.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 44.0% and a
Inozyme Pharma | 10-Q: Q2 2024 Earnings Report